# Relationship Between Procalcitonin Levels and Presence of Vesicoureteral Reflux During First Febrile Urinary Tract Infection in Children

Ilke Ozahi Ipek, Rabia Gonul Sezer, Evrim Senkal, and Abdulkadir Bozaykut

**OBJECTIVE**To investigate the association between the procalcitonin (PCT) level during the first febrile urinary tract infection (UTI) in children and the presence of vesicoureteral reflux (VUR).

VUR-associated UTI is among the primary causes of chronic renal failure in Turkey.

**METHODS** From March 2008 to November 2009, patients admitted with their first febrile UTI were

included in the present prospective hospital-based study. The serum concentrations of C-reactive protein, complete blood count, and PCT were measured. All patients underwent renal ultra-

sonography and voiding cystourethrography.

**RESULTS** Of the 66 patients who were diagnosed with UTI, 18 had VUR. The geometric mean of the PCT

levels was significantly greater in the children with VUR than in those without (P = .006). After logistic regression adjustment, the association between the PCT levels and the presence of VUR remained significant (odds ratio 5.08, 95% confidence interval [CI] 1.43-18.02). A PCT level >0.56 ng/mL had 66.7% sensitivity (95% CI 41-86.6) and 77.1% specificity (95% CI 62.7-88) for diagnosing VUR. The area under the receiver operating characteristic curve for PCT was 0.715 (95% CI, 0.56-0.86, P = .007), and the area under the curve for C-reactive protein was

0.723 (95% CI 0.58-0.86, P = .006).

**CONCLUSION** A PCT-guided strategy could help in detecting patients with VUR. Large cohort studies are needed

to define an accurate cutoff value for children who are at risk of VUR, which increases the risk of renal damage and subsequent scarring. UROLOGY 79: 883–887, 2012. © 2012 Elsevier Inc.

he cumulative incidence of urinary tract infections (UTIs) during childhood is estimated at 7.8% for girls and 1.6% for boys. UTIs are the most common indication necessitating radiographic evaluation to detect the presence of vesicoureteral reflux (VUR). VUR is found in 25%-40% of children during the evaluation of their first UTI episode.<sup>2,3</sup> With an incidence of 32.4%, VUR-associated UTIs have been reported to be the primary cause of childhood hypertension and chronic renal failure in Turkey. 4 VUR has been diagnosed in 22% of those with a first UTI and 26% of those with a second UTI in Turkish children.<sup>5</sup> The American Academy of Pediatrics recommends that ultrasonography of the kidneys and bladder be performed after the first febrile UTI in children.<sup>6</sup> Voiding cystourethrography (VCUG) should be performed in children with a recurrence of febrile UTI, renal and bladder ultrasonography exhibiting hydronephrosis, scarring, findings sug-

gestive of high-grade VUR, or obstructive uropathy. <sup>6</sup> Because renal ultrasonography alone is not satisfactory for predicting VUR, and VCUG has disadvantages, including exposure to radiation, a risk of iatrogenic UTI, and pain, new predictors are required to determine the infants at high risk of VUR.

Procalcitonin (PCT) is a very specific marker for acute bacterial infection, although it is unclear whether PCT is a hormone, a cytokine, or an acute-phase protein, studies have found that high PCT levels in the context of a bacterial infection suggest a rigorous acute immune response.<sup>7</sup> PCT can be detected in the blood 2 hours after endotoxin injection, and the increase in the PCT concentration often correlates with the severity and mortality of the disease. 7,8 Increases in PCT occur more rapidly than increases of C-reactive protein (CRP), an acute phase protein also used to differentiate between bacterial and viral infection. Many studies assessing the role of PCT in neonatal infections, invasive infections, infections of the lower respiratory tract, UTI, fever of unknown origin, and pediatric oncology have concluded PCT is a valuable tool for the early diagnosis of bacterial disease in children. 10

PCT has previously been demonstrated to be associated with renal scars and VUR.  $^{11\text{-}13}$  Because PCT values

From the Department of Pediatrics, Medipol University School of Medicine, Unkapanı, Istanbul, Turkey; and Department of Pediatrics, Zeynep Kamil Maternity and Childrens' Diseases Training and Research State Hospital, Uskudar, Istanbul, Turkey

Reprint requests: Rabia Gonul Sezer, M.D., Zeynep Kamil Hastanesi, Arakiyeci Haci Mehmet Mah, Op Dr. Burhanettin Üstünel Caddesi, Uskudar, Istanbul 34668 Turkey. E-mail: rabiagonul@hotmail.com

Submitted: October 5, 2011; received (with revisions): November 15, 2011

can be determined from venous blood samples and are generally available even in hospitals with limited facilities, we aimed to investigate the association between PCT and the presence of VUR.

### **MATERIAL AND METHODS**

The present hospital-based prospective study was conducted from March 2008 to November 2009 in the Zeynep Kamil Maternity and Childrens' Diseases Training and Research State Hospital (Istanbul, Turkey). Informed parental consent was obtained for all subjects, and the local ethics committee approved the study.

Patients who were admitted with their first febrile UTI were included in the present study. The inclusion criteria were defined as follows: patients of either sex aged 1 month to 14 years, an axillary temperature >37.2°C, and a positive urine culture with a single microorganism. The patients with the following criteria were excluded from the study: newborns, those with a history of previous UTI, a history of previous urinary tract operations, previously known uropathy (eg, congenital malformations, urolithiasis), antibiotic use at urinalysis and blood analysis, positive urine cultures with >1 organism, or negative urine cultures. Urine samples were obtained by suprapubic aspiration or transurethral catheterization in nontoilet-trained children and midstream clean-catch in toilet-trained children. Pyuria was defined as the presence of ≥5 leukocytes per a 40× objective high power field of urine. All urine samples were cultured on blood and eosin-methylene blue agar plates using a standard loop. The plates were incubated at 37°C for 24 hours, and bacteria were identified using standard methods. The diagnosis of UTI according to a positive urine culture was defined as any growth of a single bacterial pathogen from suprapubic aspiration,  $\geq 10^5$  colony-forming units/mL for midstream urine or ≥10<sup>4</sup> colony-forming units/mL of urine for transurethral catheterization.

All eligible patients with a suspected UTI were examined, and the leukocyte (WBC) counts, CRP levels, PCT levels, and urine cultures were obtained. Urinalysis was conducted for all patients. The blood and urine were sampled at admission. Empirical antibiotic treatment after blood sampling was started for patients with pyuria. Children who were unable to retain their oral intake, presented with symptoms of toxicity, or were dehydrated were hospitalized. The children with leukocyte esterase positivity were followed clinically until the culture results were obtained. The laboratory parameters of children with positive urine culture results were analyzed in the present study.

A renal ultrasound scan was obtained within the first 48 hours after confirmation of UTI by the urine culture findings. All patients had undergone VCUG within 3 months, after UTI treatment when the urine was sterile, and VUR was graded using the International System for Radiological Grading of VUR. 14

Serum CRP concentrations were measured using a nephelometric method (IMMAGE 800, Beckman Coulter, Brea, CA), and values >1 mg/dL were considered abnormal. The quantitative measurement of the PCT levels was performed using a chemiluminescence assay (Liaison, DiaSorin Laboratories, Saluggia, Italy), and values >0.5 ng/mL were considered abnormal. The PCT results were compared with the CRP values.

### **Statistical Analysis**

Statistical analysis was performed using the Statistical Package for Social Sciences, version 17.0 (SPSS, Chicago, IL). Univariate analysis was conducted using the chi-square and t tests to evaluate the relationship between the high PCT levels and VUR. A logistic regression model was used to assess the independence of this relationship. Potential confounders, including age, sex, family history of uropathy, pathologic renal ultrasonography, WBC count, and CRP (factors) were adjusted for the prediction of the presence of VUR (dependent variable). These variables were dichotomized as follows: age <12 months versus >12 months, boys versus girls, family history of uropathy versus no history, pathologic ultrasound findings versus normal findings, PCT <0.5 ng/mL versus >0.5 ng/mL, CRP <1 mg/dL versus >1 mg/dL, WBC count <15 000 mm<sup>3</sup> versus >15 000 mm<sup>3</sup>. Because all the children had fever, fever did not affect the model outcome and was not included in the model. The best model was based on the Nagelkerke R<sup>2</sup> value. The discriminating power of PCT was determined by its sensitivity and specificity for VUR. A cutoff value for PCT was determined using the receiver operating characteristic (ROC) curve. P < .05 was considered statistically significant.

#### **RESULTS**

A total of 66 children, 47 girls (71.2%) and 19 (28.8%) boys, were enrolled in our prospective study. Their mean age was  $38.62 \pm 39.21$  months (range 1-144, median 19). VUR was diagnosed in 18 children.

The mean PCT level was  $1.96 \pm 5.92$  ng/dL (range 0.1-43, median 0.39). The geometric mean of the PCT levels was significantly greater in the children with VUR than in those without (P = .006; Table 1). Of the 66 children, 39 (59.1%) had negative serum PCT levels (<0.5 ng/mL). Of the 39 patients with normal PCT levels, 5 (12.8%) had VUR (2 with grade 1 and 1 each with grade 2, 3, and 4). Logistic regression adjustment, including age, sex, ultrasound results, family history, CRP level, and WBC count as potential confounders, was applied. The best model explaining the association between the presence of VUR and the risk factors included sex, WBC count, CRP level, and PCT level (P = .02). The association between the PCT level and the presence of VUR remained significant (odds ratio 5.08, 95% confidence interval [CI] 1.43-18.02; Table 2). All the children had fever; thus, fever was not included in the model.

A PCT level >0.56 ng/mL gave a 66.7% sensitivity (95% CI 41%-86.6%) and 77.1% specificity (95% CI 62.7%-88%) for diagnosing VUR (Table 3). The area under the ROC curve for PCT was 0.715 (95% CI 0.56-0.86, P=.007). The area under the ROC curve for CRP was 0.723 (95% CI 0.58-0.86, P=.006; Fig. 1). The comparison of the ROC area of CRP and PCT was not significant (P=.9). The mean CRP level was 7.2  $\pm$  6.83 mg/dL. A significant positive correlation was found between the CRP and PCT values (r=0.28, P=.02).

The axillary temperature of the children ranged from 38° to 40.3°C. Of the 66 children, 12 (18.2%) presented with vomiting, 8 (12.1%) with stomachache, and 16 (24.2%) with other symptoms, such as costovertebral

Table 1. Baseline characteristics of children and comparison of parameters stratified by presence of vesicoureteral reflux

Age (mo)         38.37 ± 39.01         39.30 ± 40.85         .93*           Sex         .18†           Male         16 (33.3)         3 (16.7)         15 (83.3)           Female         32 (66.7)         15 (83.3)         7.8*           WBC (mm³)         14 868 ± 7232         15 338 ± 6264         .80*           CRP (mg/dL)         5.82 ± 5.04         10.87 ± 9.42         .007***           Pathogens isolated in urine culture         .582 ± 5.04         10.87 ± 9.42         .007***           Pathogens isolated in urine culture         .582 ± 5.04         10.87 ± 9.42         .007***           Pathogens isolated in urine culture         .582 ± 5.04         10.87 ± 9.42         .007***           Escherichia coli         38 (79.2)         15 (83.3)		•	* *	
Age (mo) Sex         38.37 ± 39.01         39.30 ± 40.85         .93* 1.8†           Male Female         16 (33.3) 32 (66.7)         3 (16.7)         .78*           Female         32 (66.7)         15 (83.3)         .78*           Fever (°C)         38.80 ± 0.37         38.84 ± 0.67         .78*           WBC (mm³)         14 868 ± 7232         15 338 ± 6264         .80*           CRP (mg/dL)         5.82 ± 5.04         10.87 ± 9.42         .007**           Pathogens isolated in urine culture         .582 ± 5.04         10.87 ± 9.42         .007**           Pathogens isolated in urine culture         .582 ± 5.04         15 (83.3)         .55†           Escherichia coli         38 (79.2)         15 (83.3)	Characteristic	V		
Sex         .18 <sup>†</sup> Male         16 (33.3)         3 (16.7)           Female         32 (66.7)         15 (83.3)           Fever (°C)         38.80 ± 0.37         38.84 ± 0.67         .78*           WBC (mm³)         14 868 ± 7232         15 338 ± 6264         .80*           CRP (mg/dL)         5.82 ± 5.04         10.87 ± 9.42         .007**           Pathogens isolated in urine culture		No (n = 48)	Yes (n = 18)	P Value
Male Female         16 (33.3) (316.7)         3 (16.7)         15 (83.3)         Female Fewer (°C)         32 (66.7)         15 (83.3)         7 (8*)         7 (8*)         88 (2 0.37)         38.84 ± 0.67         7.8*         7 (8*)         7 (8*)         7 (8*)         7 (8*)         7 (8*)         7 (8*)         7 (8*)         7 (8*)         7 (8*)         8 (8*)         7 (8*)         7 (8*)         8 (8*)         7 (8*)         8 (8*)         7 (8*)         8 (8*)         7 (8*)         8 (8*)         7 (8*)         8 (8*)         7 (8*)         8 (8*)         7 (8*)         8 (8*)         7 (8*)         8 (8*)         7 (8*)         8 (8*)         7 (8*)         8 (8*)         7 (8*)         8 (8*)         7 (9*)         7 (9*)         8 (9*)         7 (9*)         7 (9*)         7 (9*)         7 (8*)         8 (9*)         7 (9*)         7 (9*)         7 (9*)         8 (9*)         8 (9*)         8 (9*)         8 (9*)         9 (9*)         8 (9*)         9 (9*)<	Age (mo)	$38.37 \pm 39.01$	$39.30 \pm 40.85$	
Female 32 (66.7) 15 (83.3) Fever (°C) 38.80 ± 0.37 38.84 ± 0.67 .78* WBC (mm³) 14 868 ± 7232 15 338 ± 6264 .80* CRP (mg/dL) 5.82 ± 5.04 10.87 ± 9.42 .007** Pathogens isolated in urine culture  Escherichia coli 38 (79.2) 15 (83.3) Proteus 6 (12.5) 1 (5.6) Staphylococcus aureus 0 1 (5.6) Enterobacter Group D β-hemolytic streptococci 1 (2.1) 0 0 Klebsiella 1 (2.1) 0 0 Citrobacter freundii 1 (2.1) 0 0 Clean void 23 (74.2) 8 (25.8) PCT (ng/mL) Geometric mean 0.35 1.03 .006* Mean ± SD 1.12 ± 3.03 4.19 ± 10.07 .06** PCT group (n)  <	Sex			.18 <sup>†</sup>
Fever (°C) 38.80 ± 0.37 38.84 ± 0.67 .78* WBC (mm³) 14.868 ± 7232 15.338 ± 6.264 .80* CRP (mg/dL) 5.82 ± 5.04 10.87 ± 9.42 .007** Pathogens isolated in urine culture	Male	16 (33.3)	3 (16.7)	
WBC (mm³)         14 868 ± 7232         15 338 ± 6264         .80*           CRP (mg/dL)         5.82 ± 5.04         10.87 ± 9.42         .007***           Pathogens isolated in urine culture         .55†           Escherichia coli         38 (79.2)         15 (83.3)           Proteus         6 (12.5)         1 (5.6)           Staphylococcus aureus         0         1 (5.6)           Group D β-hemolytic streptococci         1 (2.1)         0           Klebsiella         1 (2.1)         0           Citrobacter freundii         1 (2.1)         0           Method of urine collection         .88†           Suprapubic aspiration         12 (75)         4 (25)           Transurethral catheterization         13 (68.4)         6 (31.6)           Clean void         23 (74.2)         8 (25.8)           PCT (ng/mL)         3 (74.2)         8 (25.8)           PCT group (n)         .006*           <0.5 ng/mL	Female	32 (66.7)	15 (83.3)	
CRP (mg/dL)         5.82 ± 5.04         10.87 ± 9.42         .007**           Pathogens isolated in urine culture         .55†           Escherichia coli         38 (79.2)         15 (83.3)           Proteus         6 (12.5)         1 (5.6)           Staphylococcus aureus         0         1 (5.6)           Enterobacter         1 (2.1)         0           Group D β-hemolytic streptococci         1 (2.1)         0           Klebsiella         1 (2.1)         0           Citrobacter freundii         1 (2.1)         0           Method of urine collection         .88†           Suprapubic aspiration         12 (75)         4 (25)           Transurethral catheterization         13 (68.4)         6 (31.6)           Clean void         23 (74.2)         8 (25.8)           PCT (ng/mL)         8 (25.8)           Geometric mean         0.35         1.03         .006*           Mean ± SD         1.12 ± 3.03         4.19 ± 10.07         .06**           PCT group (n)         .002*         .002*           < 0.5 ng/mL	Fever (°C)	$38.80 \pm 0.37$	$38.84 \pm 0.67$	.78*
Pathogens isolated in urine culture         .55 <sup>†</sup> Escherichia coli         38 (79.2)         15 (83.3)           Proteus         6 (12.5)         1 (5.6)           Staphylococcus aureus         0         1 (5.6)           Enterobacter         1 (2.1)         1 (5.6)           Group D β-hemolytic streptococci         1 (2.1)         0           Klebsiella         1 (2.1)         0           Citrobacter freundii         1 (2.1)         0           Method of urine collection         .88 <sup>†</sup> Suprapubic aspiration         12 (75)         4 (25)           Transurethral catheterization         13 (68.4)         6 (31.6)         2.88 <sup>†</sup> Suprapubic aspiration         12 (75)         4 (25)         4.25         4.25         2.25           Transurethral catheterization         13 (68.4)         6 (31.6)         6 (31.6)         2.25         8 (25.8)         PCT (ng/mL)         6 (31.6)         2.88 <sup>†</sup> Geometric mean         0.35         1.03         .006*         8         2.28         1.03         .006*         8           PCT group (n)         34 (70.8)         5 (27.8)         2.27.8)         2.27.8)         2.27.8)         2.27.8)         2.27.8)         3.	WBC (mm <sup>3</sup> )	$14868\pm7232$	$15338\pm6264$	.80*
Pathogens isolated in urine culture         .55†           Escherichia coli         38 (79.2)         15 (83.3)           Proteus         6 (12.5)         1 (5.6)           Staphylococcus aureus         0         1 (5.6)           Enterobacter         1 (2.1)         1 (5.6)           Group D β-hemolytic streptococci         1 (2.1)         0           Klebsiella         1 (2.1)         0           Citrobacter freundii         1 (2.1)         0           Method of urine collection         .88†           Suprapubic aspiration         12 (75)         4 (25)           Transurethral catheterization         13 (68.4)         6 (31.6)           Clean void         23 (74.2)         8 (25.8)           PCT (ng/mL)	CRP (mg/dL)	$5.82 \pm 5.04$	$10.87 \pm 9.42$	.007**
Proteus         6 (12.5)         1 (5.6)           Staphylococcus aureus         0         1 (5.6)           Enterobacter         1 (2.1)         1 (5.6)           Group D β-hemolytic streptococci         1 (2.1)         0           Klebsiella         1 (2.1)         0           Citrobacter freundii         1 (2.1)         0           Method of urine collection         .88†           Suprapubic aspiration         12 (75)         4 (25)           Transurethral catheterization         13 (68.4)         6 (31.6)           Clean void         23 (74.2)         8 (25.8)           PCT (ng/mL)         36 (25.8)         1.03         .006*           Mean ± SD         1.12 ± 3.03         4.19 ± 10.07         .06**           PCT group (n)         .002 ± 10.00         .002 ± 10.00         .002 ± 10.00           <0.5 ng/mL         34 (70.8)         5 (27.8)         .002 ± 10.00           Normal         35 (72.9)         13 (72.2)         .35†           Normal         35 (72.9)         13 (72.2)         .35†           Pelviectasis         5 (10.4)         3 (16.7)         .94           Hydronephrosis         2 (4.2)         0 (0)         .000           Nephrolith				.55 <sup>†</sup>
Staphylococcus aureus         0         1 (5.6)           Enterobacter         1 (2.1)         1 (5.6)           Group D β-hemolytic streptococci         1 (2.1)         0           Klebsiella         1 (2.1)         0           Citrobacter freundii         1 (2.1)         0           Method of urine collection         .88†           Suprapublic aspiration         12 (75)         4 (25)           Transurethral catheterization clean void         23 (74.2)         8 (25.8)           PCT (ng/mL)         6 (31.6)         6 (31.6)           Geometric mean         0.35         1.03         .006*           Mean ± SD         1.12 ± 3.03         4.19 ± 10.07         .06**           PCT group (n)         .005*         .002**         .002**           <0.5 ng/mL	Escherichia coli	38 (79.2)	15 (83.3)	
Enterobacter         1 (2.1)         1 (5.6)           Group D β-hemolytic streptococci         1 (2.1)         0           Klebsiella         1 (2.1)         0           Citrobacter freundii         1 (2.1)         0           Method of urine collection         .88†           Suprapubic aspiration         12 (75)         4 (25)           Transurethral catheterization         13 (68.4)         6 (31.6)           Clean void         23 (74.2)         8 (25.8)           PCT (ng/mL)         8 (25.8)           Geometric mean         0.35         1.03         .006*           Mean ± SD         1.12 ± 3.03         4.19 ± 10.07         .06*†           PCT group (n)         .002*†         .002*†           < 0.5 ng/mL	Proteus	6 (12.5)	1 (5.6)	
Group D β-hemolytic streptococci         1 (2.1)         0           Klebsiella         1 (2.1)         0           Citrobacter freundii         1 (2.1)         0           Method of urine collection         .88†           Suprapubic aspiration         12 (75)         4 (25)           Transurethral catheterization         13 (68.4)         6 (31.6)           Clean void         23 (74.2)         8 (25.8)           PCT (ng/mL)         36 (25.8)         1.03         .006*           Mean ± SD         1.12 ± 3.03         4.19 ± 10.07         .06*†           PCT group (n)         0.5 ng/mL         34 (70.8)         5 (27.8)         .002*† $< 0.5 \text{ ng/mL}$ 34 (70.8)         5 (27.8)         .002*† $< 0.5 \text{ ng/mL}$ 34 (70.8)         5 (27.8)         .35†           Normal         35 (72.9)         13 (72.2)         .35†           Pelviectasis         5 (10.4)         3 (16.7)         .35†           Hydronephrosis         2 (4.2)         0 (0)         .15.6)           Other         6 (12.5)         1 (5.6)         .13†           Family history         .13†	Staphylococcus aureus	0	1 (5.6)	
Klebsiella       1 (2.1)       0         Citrobacter freundii       1 (2.1)       0         Method of urine collection       .88 <sup>†</sup> Suprapubic aspiration       12 (75)       4 (25)         Transurethral catheterization Clean void       23 (74.2)       8 (25.8)         PCT (ng/mL)       8 (25.8)         Geometric mean       0.35       1.03       .006*         Mean ± SD       1.12 ± 3.03       4.19 ± 10.07       .06**         PCT group (n)       .002**       .002**         < 0.5 ng/mL       34 (70.8)       5 (27.8)       .002**         < >0.5 ng/mL       14 (292)       13 (72.2)       .35*         Urinary ultrasound findings       .35 (72.9)       13 (72.2)       .35*         Normal       35 (72.9)       13 (72.2)       .35*         Pelviectasis       5 (10.4)       3 (16.7)       .40*         Hydronephrosis       2 (4.2)       0 (0)       .00*         Nephrolithiasis       0 (0)       1 (5.6)       .50*         Other       6 (12.5)       1 (5.6)       .13*         Family history       .38 (79.2)       17 (94.4)       .13*	Enterobacter	1 (2.1)	1 (5.6)	
Citrobacter freundii       1 (2.1)       0         Method of urine collection       .88†         Suprapubic aspiration       12 (75)       4 (25)         Transurethral catheterization       13 (68.4)       6 (31.6)         Clean void       23 (74.2)       8 (25.8)         PCT (ng/mL)       8 (25.8)         Geometric mean       0.35       1.03       .006*         Mean ± SD       1.12 ± 3.03       4.19 ± 10.07       .06*†         PCT group (n)       5 (27.8)       .002*†*         < 0.5 ng/mL	Group D $\beta$ -hemolytic streptococci	1 (2.1)	0	
Citrobacter freundii       1 (2.1)       0         Method of urine collection       .88†         Suprapubic aspiration       12 (75)       4 (25)         Transurethral catheterization       13 (68.4)       6 (31.6)         Clean void       23 (74.2)       8 (25.8)         PCT (ng/mL)       8 (25.8)         Geometric mean       0.35       1.03       .006*         Mean ± SD       1.12 ± 3.03       4.19 ± 10.07       .06*†         PCT group (n)       5 (27.8)       .002*†*         < 0.5 ng/mL	Klebsiella	1 (2.1)	0	
Suprapubic aspiration       12 (75)       4 (25)         Transurethral catheterization       13 (68.4)       6 (31.6)         Clean void       23 (74.2)       8 (25.8)         PCT (ng/mL)       8 (25.8)         Geometric mean       0.35       1.03       .006*         Mean ± SD       1.12 ± 3.03       4.19 ± 10.07       .06**         PCT group (n)       .002**       .002**         < 0.5 ng/mL	Citrobacter freundii		0	
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Method of urine collection			.88 <sup>†</sup>
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Suprapubic aspiration	12 (75)	4 (25)	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Transurethral catheterization	13 (68.4)	6 (31.6)	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Clean void	23 (74.2)	8 (25.8)	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	PCT (ng/mL)			
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Geometric mean	0.35	1.03	.006*
<0.5 ng/mL	Mean $\pm$ SD	$1.12 \pm 3.03$	$4.19 \pm 10.07$	
>0.5 ng/mL       14 (292)       13 (72.2)         Urinary ultrasound findings       .35†         Normal       35 (72.9)       13 (72.2)         Pelviectasis       5 (10.4)       3 (16.7)         Hydronephrosis       2 (4.2)       0 (0)         Nephrolithiasis       0 (0)       1 (5.6)         Other       6 (12.5)       1 (5.6)         Family history       .13†         No       38 (79.2)       17 (94.4)	PCT group (n)			.002††
Urinary ultrasound findings       .35†         Normal       35 (72.9)       13 (72.2)         Pelviectasis       5 (10.4)       3 (16.7)         Hydronephrosis       2 (4.2)       0 (0)         Nephrolithiasis       0 (0)       1 (5.6)         Other       6 (12.5)       1 (5.6)         Family history       .13†         No       38 (79.2)       17 (94.4)	<0.5 ng/mL	34 (70.8)	5 (27.8)	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	>0.5 ng/mL	14 (292)	13 (72.2)	
Pelviectasis     5 (10.4)     3 (16.7)       Hydronephrosis     2 (4.2)     0 (0)       Nephrolithiasis     0 (0)     1 (5.6)       Other     6 (12.5)     1 (5.6)       Family history     .13 <sup>†</sup> No     38 (79.2)     17 (94.4)	Urinary ultrasound findings			.35 <sup>†</sup>
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Normal	35 (72.9)	13 (72.2)	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Pelviectasis	5 (10.4)	3 (16.7)	
Other $6 \ (12.5)$ $1 \ (5.6)$ Family history $1.13^{\dagger}$ $1.13^{\dagger$	Hydronephrosis	2 (4.2)		
Family history .13 <sup>†</sup> No 38 (79.2) 17 (94.4)	Nephrolithiasis	0 (0)	1 (5.6)	
No 38 (79.2) 17 (94.4)	Other	6 (12.5)	1 (5.6)	
	Family history			.13 <sup>†</sup>
Yes 10 (20.8) 1 (5.6)	No	38 (79.2)	17 (94.4)	
· / · · · /	Yes	10 (20.8)	1 (5.6)	

WBC, leukocyte; CRP, C-reactive protein; PCT, procalcitonin.

Data presented as mean  $\pm$  SD or numbers, with percentages in parentheses.

Table 2. Analysis of role of various factors in detecting vesicoureteral reflux on multivariate analysis

Variable	Standard Error	P Value	Odds Ratio	95% Confidence Interval
CRP >1 mg/dL	1.17	0.628	1.76	1.17-17.51
PCT >0.5 ng/dL	0.64	0.012	5.08	1.43-18.02
WBC >15 000 mm <sup>3</sup>	0.62	0.367	1.76	0.51-6.03
Female sex	0.78	0.451	1.80	0.38-8.37

Abbreviations as in Table 1.

angle tenderness, dysuria, and enuresis, in addition to fever. Pyuria was present in 55 patients and nitrate positivity in 26 patients. Leukocyte esterase positivity was observed in 29 urine samples. No significant difference was found with regard to age, sex, fever status, WBC count, isolated organism found in the urine culture, method of urine collection, or renal ultrasound results of the patients with and without VUR. No correlation was found between the age of the children and the PCT levels (r = -0.06, P = .58), and no significant difference was detected between the PCT level when stratified by sex (P > .05).

A comparison of PCT levels according to the VUR grade did not reveal any statistically significant results, although the geometric mean of the PCT levels was relatively greater for grade 1 VUR (1.77 ng/dL in grade 1, 0.41 ng/dL in grade 2, and 0.84 ng/dL in grade 3; P = .34).

## **COMMENT**

In the presence of a febrile, culture-documented UTI, elevations in PCT correlated with the presence of VUR and might prompt an earlier evaluation with VCUG.

UROLOGY 79 (4), 2012 **885** 

<sup>\*</sup> t Test.

<sup>&</sup>lt;sup>†</sup> Chi-square test.


<sup>\*</sup> Statistically significant.

**Table 3.** Sensitivity, specificity, positive predictive value, and negative predictive value of procalcitonin levels in predicting vesicoureteral reflux

PCT (ng/mL)	Sensitivity (%)	Specificity (%)	Positive Likelihood Ratio	Negative Likelihood Ratio	Positive Predictive Value (%)	Negative Predictive Value (%)
≥0.5	72.2 (46.5-90.2)	70.8 (55.9-83)	2.48	0.39	48.1	87.2
≥0.53	66.7 (41-86.6)	72.9 (58.2-84.7)	2.46	0.46	48	85.4
≥0.55	66.7 (41-86.6)	75 (60.4-86.3)	2.67	0.44	50	85.7
≥0.56	66.7 (41-86.6)	77.1 (62.7-88)	2.91	0.43	52.2	86
≥0.6	61.1 (35.8-82.6)	77.1 (62.7-88)	2.67	0.5	50	84.1
≥0.8	55.6 (30.8-78.4)	79.2 (65-89.5)	2.67	0.56	50	82.6

PCT, procalcitonin.

Data in parentheses are 95% confidence intervals.



**Figure 1.** ROC curve for specificity and sensitivity of PCT and CRP measurements. PCT area under ROC curve of 0.715 (95% CI 0.591-0.820, P = .007). Area under ROC curve for CRP was 0.723 (95% CI 0.58-0.86, P = .006).

The early diagnosis of VUR is essential owing to the high mortality and morbidity associated with the condition. Because of the inconvenience of VCUG and the inaccuracy of ultrasonography for the detection of VUR, new diagnostic methods are continuously being sought. A test that distinguishes VUR without requiring the use of an imaging technique would help in treatment planning.

PCT, a precursor of calcitonin, was first discovered in 1993 to be an infection marker by Assicot et al. PCT levels increase 3-4 hours after bacterial lipopolysaccharide exposure, peak at approximately 6 hours, and then plateau for ≤24 hours. PCT has a half-life of 25-30 hours. Studies have confirmed PCT to be an indicator of systemic bacterial infection. In healthy individuals, the PCT level is usually <0.1 ng/mL; however, in bacterial infections, the level can be >1000 ng/mL. A review concerning the use of PCT concluded that PCT had greater sensitivity and specificity than the CRP level or WBC count in differentiating between upper and lower UTI. In a study assessing the

predictive capability of PCT levels among children with fever without a known source, PCT was able to detect all *Escherichia coli* bacteremia in patients with UTI. <sup>15</sup> PCT with a cutoff of  $\geq$ 0.5 ng/mL had a sensitivity of 77% and specificity of 64%. <sup>15</sup> Andreola et al <sup>16</sup> found a sensitivity of 73% and a specificity of 76%, with a UTI rate of 53%.

In a retrospective, hospital-based, single-center cohort study of 136 patients with UTI, 25% of the sample had VUR.<sup>13</sup> High PCT levels (≥0.5 ng/mL) were associated with reflux at a sensitivity of 85% (95% CI 70%-94%) and specificity of 44% (95% CI 35%-54%). 13 The PCT level of the patients increased with VUR grade. The investigators explained this association by suggesting that the risk of renal scarring with high-grade VUR is increased. 13 Two studies by Leroy et al<sup>17,18</sup> have also confirmed the relationship between PCT and VUR. A PCT level of ≥0.5 ng/mL gave a sensitivity of 83% (95% CI 71%-91%) and a specificity of 43% (95% CI 38%-47%) for high-grade VUR, regardless of the presence of early renal parenchymal involvement in children with a first UTI. 18 The sensitivity of PCT (≥0.5 ng/mL) as a predictor of VUR was 75% (95% CI 66%-83%) for all grades of VUR, and the specificity was 43% (95% CI 37%-48%). 17 Pecile et al 19 investigated 100 children presenting with their first febrile UTI. In that study, using a cutoff value of 0.8 ng/mL, the sensitivity and specificity of PCT was 83.3% and 93.6%, respectively. In our study, using a cutoff value of 0.5 ng/mL, the sensitivity and specificity was 72.2% (95% CI 46.5%-90.2%) and 70.8% (95% CI 55.9%-83%), respectively. The retrospective design of the study by Leroy et al<sup>13</sup> and the inclusion of urine culture findings from sterile bags might explain the differences in the specificity values between our study and theirs.

Prat et al<sup>11</sup> did not find a correlation between the serum PCT level and VUR; however, in their study, the serum PCT levels correlated significantly with the presence of renal scars in children with UTIs. Using a cutoff of 1 ng/mL, the sensitivity and specificity of PCT for distinguishing between UTIs with and without renal damage was 92.3% and 61.9%, respectively. The corresponding positive and negative predictive values were 32% and 97.5% for PCT.<sup>11</sup>

Kotoula et al<sup>20</sup> studied 57 children with UTIs and sought to determine the relationship between PCT and renal parenchymal inflammation. They found that of the 51 patients who underwent VCUG, 14 had VUR. The PCT

**886** UROLOGY 79 (4), 2012

levels of the patients with a renal defect covering 4%-10% of the surface area of their kidney, as assessed by technetium-99m dimercaptosuccinic acid, did not differ in patients with or without VUR. The PCT level was significantly greater in the children with VUR and persistent renal lesions, as assessed by renal dimercaptosuccinic acid scanning at 6 months, than in the children without VUR. The area under the ROC curve was 0.988 for PCT. The simultaneous presence of PCT of  $\geq$ 0.85 mg/mL and CRP of  $\geq$ 3.5 mg/dL resulted in a sensitivity of 78% and specificity of 100% in the prediction of renal parenchymal inflammation. PCT has been shown to be more reliable than the erythrocyte sedimentation rate, CRP, or WBC count for predicting permanent renal damage. PCD of the sedimentation rate area of the surface o

New studies have indicated the cost-effectiveness of PCT and demonstrated that a PCT-guided antibiotic strategy can reduce the overall costs of care (price of PCT, Canadian \$49.42).<sup>21</sup> In France, PCT analysis costs €10-€15.<sup>22</sup> In our state hospital, the cost of CRP, PCT, complete blood count, and VCUG is 4.95 Turkish liras (€1 equals ~2.6 Turkish liras), 28.05 Turkish liras, 3.30 Turkish liras, and 69.96 Turkish liras, respectively. The cost, availability, and simplicity of PCT measurement compared with the radiologic techniques would make it a useful tool for clinical use.

Our data are in agreement with those of previous studies indicating that PCT is a reliable indicator of VUR in patients who are admitted with their first febrile UTI. One limitation of our study was the small sample size. Additional studies with larger sample sizes should be conducted. We did not record how long the symptoms were present before blood collection, which could have altered the PCT levels. In addition, we did not study the relationship between the PCT levels and renal scintigraphy results, because of the absence of a nuclear medicine facility in our hospital. PCT cannot be presented as the reference standard for VUR detection; however, a low PCT level indicates a low risk of VUR and a high serum value correlated with a high risk of VUR. Because the negative predictive value of PCT is not 100% but the value is still greater than that observed with CRP and WBC, PCT measurement will be useful in all diagnoses.

### **CONCLUSIONS**

PCT measurements could be useful in identifying patients at risk of severe UTI. A PCT-guided strategy could be helpful in detecting patients with VUR and reduce unnecessary VCUGs. Large cohort studies are needed to define an accurate cutoff value for children who are at risk of VUR, which increases the risk of renal damage and subsequent scarring.

#### References

 Hellström A, Hanson E, Hansson S, et al. Association between urinary symptoms at 7 years old and previous urinary tract infection. Arch Dis Child. 1991;66:232-234.

- Greenfield SP, Wan J. Vesicoureteral reflux: practical aspects of evaluation and management. Pediatr Nephrol. 1996;10:789-794.
- Hellerstein S. Urinary tract infections: old and new concepts. Pediatr Clin North Am. 1995;42:1433-1456.
- Sirin A, Emre S, Alpay H, et al. etiology of chronic renal failure in Turkish children. Pediatr Nephrol. 1995;9:549-552.
- Peru H, Bakkaloglu SA, Soylemezoglu O, et al. The relationship between urinary tract infections and vesicoureteral reflux in Turkish children. *Int Urol Nephrol.* 2009;41:947-951.
- American Academy of Pediatrics Subcommittee on Urinary Tract Infection; Steering Committee on Quality Improvement and Management. Urinary tract infection: clinical practice guideline for the diagnosis and management of the initial UTI in febrile infants and children 2 to 24 months. *Pediatrics*. 2011;128:595-610.
- Leroy S, Gervaix A. Procalcitonin: a key marker in children with urinary tract infection. Adv Urol. 2011;2011:397618.
- Dandona P, Nix D, Wilson MF, et al. Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab. 1994;79:1605-1608.
- Assicot M, Gendrel D, Carsin H, et al. High serum procalcitonin concentrations in patients with sepsis and infection. *Lancet*. 1993; 341:515-518.
- van Rossum AM, Wulkan RW, Oudesluys-Murphy AM. Procalcitonin as an early marker of infection in neonates and children. *Lancet Infect Dis.* 2004;4:620-630.
- Prat C, Domínguez J, Rodrigo C, et al. Elevated serum procalcitonin values correlate with renal scarring in children with urinary tract infection. *Pediatr Infect Dis J.* 2003;22:438-442.
- Benador N, Siegrist CA, Gendrel D, et al. Procalcitonin is a marker of severity of renal lesions in pyelonephritis. *Pediatrics*. 1998;102: 1422-1425.
- Leroy S, Adamsbaum C, Marc E, et al. Procalcitonin as a predictor of vesicoureteral reflux in children with a first febrile urinary tract infection. *Pediatrics*. 2005;115:706-709.
- Lebowitz RL, Olbing H, Parkkulainen KV, et al. International system of radiographic grading of vesicoureteric reflux. International Reflux Study in Children. Pediatr Radiol. 1985;15:105-109.
- Manzano S, Bailey B, Girodias JB, et al. impact of procalcitonin on the management of children aged 1 to 36 months presenting with fever without source: a randomized controlled trial. Am J Emerg Med. 2010;28:647-653.
- Andreola B, Bressan S, Callegaro S, et al: Procalcitonin and C-reactive protein as diagnostic markers of severe bacterial infections in febrile infants and children in the emergency department. *Pediatr Infect Dis J.* 2007;26:672-677.
- Leroy S, Romanello C, Galetto-Lacour A, et al. Procalcitonin to reduce the number of unnecessary cystographies in children with a urinary tract infection: a European validation study. *J Pediatr*. 2007;150:89-95.
- Leroy S, Romanello C, Galetto-Lacour A, et al. Procalcitonin is a predictor for high-grade vesicoureteral reflux in children: metaanalysis of individual patient data. J Pediatr. 2011;159:644-651.
- Pecile P, Miorin E, Romanello C, et al. Procalcitonin: a marker of severity of acute pyelonephritis among children. *Pediatrics*. 2004; 114:249-254.
- Kotoula A, Gardikis S, Tsalkidis A, et al. comparative efficacies of procalcitonin and conventional inflammatory markers for prediction of renal parenchymal inflammation in pediatric first urinary tract infection. *Urology*. 2009;73:782-786.
- Heyland DK, Johnson AP, Reynolds SC, et al. Procalcitonin for reduced antibiotic exposure in the critical care setting: a systematic review and an economic evaluation. Crit Care Med. 2011;39:1792-1799.
- Bouadma L, Luyt CE, Tubach F, et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (pro rata trial): a multicenter randomised controlled trial. *Lancet*. 2010; 375:463-474.

UROLOGY 79 (4), 2012 **887**